Share this article:
Roger Lias

Roger Lias

Tustin-based Avid Bioservices Inc. (Nasdaq: CDMO) reported fiscal first-quarter revenue fell 54% to $12.6 million from the same period a year ago but the figure topped analyst estimates and the company reaffirmed full year revenue guidance in a range of $51 million to $55 million.

Avid, which was previously the cash-generating biologics manufacturing arm of Peregrine Pharmaceuticals Inc., attributed the revenue decline to lower demand from its two biggest customers.

Get the latest OC business and Coronavirus updates

Its loss widened to $2 million from $1.2 million a year ago.

Shares traded recently at about a $380 million market cap.

Chief Executive Roger Lias said on a conference call that Avid is working to build a more diverse customer portfolio and is well positioned to capture more business in the global biologics production market. The market “is currently valued at over $250 billion a year, with a market for products that we manufacture at Avid,” he said.

Lias became chief executive last December, replacing Steven King; the company changed its name to Avid in January and sold its clinical-stage cancer drug in February to Oncologie Inc.